Association of hypermagnesemia and blood pressure in the critically ill

Journal of Hypertension

Volumn 31, Issue 11, 2013, Pages 2136-2141

  Celi, Leo A ^a,b   Scott, Daniel J ^b   Lee, Joon ^b,c   Nelson, Rachel ^a   Alper, Seth L ^a   Mukamal, Kenneth J ^a   Mark, Roger G ^b   Danziger, John ^a  

^a Beth Israel Deaconess Medical Center   (Canada)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^c UNIVERSITY OF WATERLOO   (Canada)

Author keywords

blood pressure; hypermagnesemia; hypotension; magnesium; vasopressor use

Indexed keywords

MAGNESIUM; VASOCONSTRICTOR AGENT;

AGED; BLOOD; BLOOD PRESSURE; CRITICAL ILLNESS; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; INTENSIVE CARE UNIT; MALE; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY;

AGED; BLOOD PRESSURE; CRITICAL ILLNESS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INTENSIVE CARE UNITS; MAGNESIUM; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VASOCONSTRICTOR AGENTS;

EID: 84885620541     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283642f18     Document Type: Article

References (44)

1. Guerrero-Romero F, Tamez-Perez HE, Gonzalez-Gonzalez G, Salinas-Martinez AM, Montes-Villarreal J, Trevino-Ortiz JH, et al. Oral magnesium supplementation improves insulin sensitivity in nondiabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial. Diabetes Metab 2004; 30:253-258.
2. Rodriguez-Moran M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: A randomized double-blind controlled trial. Diabetes Care 2003; 26:1147-1152.
3. Guerrero-Romero F, Rodriguez-Moran M. Low serum magnesium levels and metabolic syndrome. Acta Diabetol 2002; 39:209-213.
4. Rodriguez-Moran M, Guerrero-Romero F. Serum magnesium and C-reactive protein levels. Arch Dis Child 2008; 93:676-680.
5. Guerrero-Romero F, Rodriguez-Moran M. Relationship between serum magnesium levels and C-reactive protein concentration, in nondiabetic, nonhypertensive obese subjects. Int J Obes Relat Metab Disord 2002; 26:469-474.
6. Nozue T, Kobayashi A, Uemasu F, Takagi Y, Sako A, Endoh H. Magnesium status, serum HDL cholesterol, and apolipoprotein A-1 levels. J Pediatr Gastroenterol Nutr 1995; 20:316-318.
7. Yogi A, Callera GE, Antunes TT, Tostes RC, Touyz RM. Vascular biology of magnesium and its transporters in hypertension. Magnes Res 2010; 23:S207-S215.
8. Yogi A, Callera GE, Antunes TT, Tostes RC, Touyz RM. Transient receptor potential melastatin 7 (TRPM7) cation channels, magnesium and the vascular system in hypertension. Circ J 2011; 75:237-245.
9. Touyz RM, Laurant P, Schiffrin EL. Effect of magnesium on calcium responses to vasopressin in vascular smooth muscle cells of spontaneously hypertensive rats. J Pharmacol Exp Ther 1998; 284:998-1005.
10. Agus ZS, Kelepouris E, Dukes I, Morad M. Cytosolic magnesium modulates calcium channel activity in mammalian ventricular cells. Am J Physiol 1989; 256:C452-C455.
11. Laurant P, Touyz RM, Schiffrin EL. Effect of magnesium on vascular tone and reactivity in pressurized mesenteric resistance arteries from spontaneously hypertensive rats. Can J Physiol Pharmacol 1997; 75:293-300.
12. Sanjuliani AF, de Abreu Fagundes VG, Francischetti EA. Effects of magnesium on blood pressure and intracellular ion levels of Brazilian hypertensive patients. Int J Cardiol 1996; 56:177-183.
13. Barbagallo M, Dominguez LJ, Resnick LM. Magnesium metabolism in hypertension and type 2 diabetes mellitus.Am J Ther 2007; 14:375-385.
14. Hatzistavri LS, Sarafidis PA, Georgianos PI, Tziolas IM, Aroditis CP, Zebekakis PE, et al. Oral magnesium supplementation reduces ambulatory blood pressure in patients with mild hypertension. Am J Hypertens 2009; 22:1070-1075.
15. Yamamoto ME, Applegate WB, Klag MJ, Borhani NO, Cohen JD, Kirchner KA, et al. Lack of blood pressure effect with calcium and magnesium supplementation in adults with high-normal blood pressure. Results from Phase I of the Trials of Hypertension Prevention (TOHP). Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Ann Epidemiol 1995; 5:96-107.
16. Guerrero-Romero F, Rodriguez-Moran M. The effect of lowering blood pressure by magnesium supplementation in diabetic hypertensive adults with low serum magnesium levels: A randomized, double-blind, placebo-controlled clinical trial. J Hum Hypertens 2009; 23:245-251.
17. Dickinson HO, Nicolson DJ, Campbell F, Cook JV, Beyer FR, Ford GA, et al. Magnesium supplementation for the management of essential hypertension in adults. Cochrane Database Syst Rev 2006;CD004640.
18. Mizushima S, Cappuccio FP, Nichols R, Elliott P. Dietary magnesium intake and blood pressure: A qualitative overview of the observational studies. J Hum Hypertens 1998; 12:447-453.
19. Laurant P, Berthelot A. Influence of endothelium on Mg(2+)-induced relaxation in noradrenaline-contracted aorta from DOCA-salt hypertensive rat. Eur J Pharmacol 1994; 258:167-172.
20. Sontia B, Montezano AC, Paravicini T, Tabet F, Touyz RM. Downregulation of renal TRPM7 and increased inflammation and fibrosis in aldosterone-infused mice: effects of magnesium. Hypertension 2008; 51:915-921.
21. Touyz RM, Milne FJ. Magnesium supplementation attenuates, but does not prevent, development of hypertension in spontaneously hypertensive rats. Am J Hypertens 1999; 12:757-765.
22. Schmitz C, Perraud AL, Johnson CO, Inabe K, Smith MK, Penner R, et al. Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7. Cell 2003; 114:191-200.
23. Touyz RM. Transient receptor potential melastatin 6 and 7 channels, magnesium transport, and vascular biology: implications in hypertension. Am J Physiol Heart Circ Physiol 2008; 294:H1103-H1118.
24. DiCarlo LA Jr, Morady F, de Buitleir M, Krol RB, Schurig L, Annesley TM. Effects of magnesium sulfate on cardiac conduction and refractoriness in humans. J Am Coll Cardiol 1986; 7:1356-1362.
25. Chernow B, Bamberger S, Stoiko M, Vadnais M, Mills S, Hoellerich V, et al. Hypomagnesemia in patients in postoperative intensive care. Chest 1989; 95:391-397.
26. Saeed M, Villarroel M, Reisner AT, Clifford G, Lehman LW, Moody G, et al. Multiparameter Intelligent Monitoring in Intensive Care II: A public-access intensive care unit database. Crit Care Med 2011; 39:952-960.
27. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998; 36:8-27.
28. Danziger J, William JH, Scott DJ, Lee J, Lehman LW, Mark RG, Mukamal KJ. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int 2013; 83:692-699.
29. Widman L, Wester PO, Stegmayr BK, Wirell M. The dose-dependent reduction in blood pressure through administration of magnesium. A double blind placebo controlled cross-over study. Am J Hypertens 1993; 6:41-45.
30. Cappuccio FP, Markandu ND, Beynon GW, Shore AC, Sampson B, MacGregor GA. Lack of effect of oral magnesium on high blood pressure: A double blind study. BMJ (Clin Res Ed) 1985; 291:235-238.
31. Sacks FM, Willett WC, Smith A, Brown LE, Rosner B, Moore TJ. Effect on blood pressure of potassium, calcium, and magnesium in women with low habitual intake. Hypertension 1998; 31:131-138.
32. Henderson DG, Schierup J, Schodt T. Effect of magnesium supplementation on blood pressure and electrolyte concentrations in hypertensive patients receiving long term diuretic treatment. BMJ (Clin Res Ed) 1986; 293:664-665.
33. Patki PS, Singh J, Gokhale SV, Bulakh PM, Shrotri DS, Patwardhan B. Efficacy of potassium and magnesium in essential hypertension: A double-blind, placebo controlled, crossover study. BMJ 1990; 301: 521-523.
34. Salem S, Bruck H, Bahlmann FH, Peter M, Passlick-Deetjen J, Kretschmer A, et al. Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol 2012; 35:31-39.
35. Kircelli F, Peter ME, Sevinc OK, Celenk FG, Yilmaz M, Steppan S, et al. Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner. Nephrol Dial Transplant 2012; 27:514-521.
36. Louvet L, Buchel J, Steppan S, Passlick-Deetjen J, Massy ZA. Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. Nephrol Dial Transplant 2013; 28:869-878.
37. De Schutter TM, Behets GJ, Geryl H, Peter ME, Steppan S, Gundlach K, et al. Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia. Kidney Int 2013.
38. Ishimura E, Okuno S, Yamakawa T, Inaba M, Nishizawa Y. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res 2007; 20:237-244.
39. Schlingmann KP, Sassen MC, Weber S, Pechmann U, Kusch K, Pelken L, et al. Novel TRPM6 mutations in 21 families with primary hypomagnesemia and secondary hypocalcemia. J Am Soc Nephrol 2005; 16:3061-3069.
40. Schlingmann KP, Weber S, Peters M, Niemann Nejsum L, Vitzthum H, Klingel K, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 2002; 31:166-170.
41. He Y, Yao G, Savoia C, Touyz RM. Transient receptor potential melastatin 7 ion channels regulate magnesium homeostasis in vascular smooth muscle cells: role of angiotensin II. Circ Res 2005; 96:207-215.
42. Touyz RM, He Y, Montezano AC, Yao G, Chubanov V, Gudermann T, et al. Differential regulation of transient receptor potential melastatin 6 and 7 cation channels by ANG II in vascular smooth muscle cells from spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2006; 290:R73-R78.
43. Yang Z, Wang J, Altura BT, Altura BM. Extracellular magnesium deficiency induces contraction of arterial muscle: role of PI3-kinases and MAPK signaling pathways. Pflugers Arch 2000; 439:240-247.
44. Laurant P, Berthelot A. Endothelin-1-induced contraction in isolated aortae from normotensive and DOCA-salt hypertensive rats: effect of magnesium. Br J Pharmacol 1996; 119:1367-1374. Bioengineering